Bio-Works Technologies TO 2 Options Increase Share Capital

On July 14, 2025, Bio-Works Technologies AB concluded the third exercise period for their series TO 2 warrants, initially issued during the company's rights issue in August 2024. The exercise resulted in 1,637,481 TO 2 warrants being converted into shares, raising 1,637,481 SEK before emission costs for the company. This marks a pivotal moment in Bio-Works' financial strategy as it continues to expand its capital base.

With this exercise, the total number of shares in Bio-Works has increased to 80,370,942, and the share capital has grown to 8,037,094.2 SEK. While this capital influx is promising, it also results in a dilution effect of approximately 2.04% for existing shareholders who did not participate in the option exercise.

The TO 2 options will continue to be available for trading on the Spotlight Stock Market, with 36,568,428 options remaining. Investors will have further opportunities to exercise these options quarterly until the third quarter of 2027, with the next period set for October 1-14, 2025. This structured approach provides investors with flexibility and the potential for strategic engagement with Bio-Works' growth trajectory.

For those considering investment, Bio-Works presents a unique opportunity. The company's focus on biomolecule purification and its global reach in bioprocessing solutions position it well in the growing biotech industry. The steady increase in shares and capital through the TO 2 options is a testament to investor confidence and the company's robust financial health.

Given Bio-Works' strategic positioning and growth potential, investors might consider holding their current positions or buying more shares during future exercise periods. The consistent capital growth and the company's vision to be a reliable partner in the biotech industry suggest a promising future.